# Intravitreal Topotecan for Prevention or Treatment of Proliferative Vitreoretinopathy in Retinal Detachment

> **NCT06818721** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Unity Health Toronto** · enrollment: 394 (estimated)

## Conditions studied

- Retinal Detachment Rhegmatogenous
- Proliferative Vitreoretinopathy

## Interventions

- **DRUG:** Intravitreal topotecan
- **PROCEDURE:** Retinal detachment surgery

## Key facts

- **NCT ID:** NCT06818721
- **Lead sponsor:** Unity Health Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-03
- **Primary completion:** 2027-04
- **Final completion:** 2027-04
- **Target enrollment:** 394 (ESTIMATED)
- **Last updated:** 2025-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06818721

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06818721, "Intravitreal Topotecan for Prevention or Treatment of Proliferative Vitreoretinopathy in Retinal Detachment". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT06818721. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*